Health and well-being in communities
To improve access and support people in vulnerable communities, we make targeted product and financial donations to programmes run by local and global partners that are designed to be sustainable in the long term. We also encourage our employees to volunteer their time and expertise. In 2015, we invested £208 million in communities around the world.
Discover more about our programmes
Our philosophy is to target support on selected health and educational programmes that are innovative, sustainable and produce tangible results. The programmes we support share our vision of enhancing healthcare, and where possible they offer opportunities to involve GSK employees in assisting communities where we do business. We are working across the world with local charities to improve healthcare and education outcomes in those countries.
Partnering to save one million children’s lives
Through our partnership with Save the Children we are combining our capabilities in R&D, supply chain, procurement and vaccines with the charity’s expertise working with the most vulnerable children. Together we are delivering tangible results. To date, we have reached over 1.3 million children. Over 23,500 under-fives have been fully immunised, over 125,000 children have been treated for diarrhoea, malaria or pneumonia, and over one million children have been screened for malnutrition. Using insights and on-the-ground knowledge from Save the Children, we have been working to reformulate the antiseptic chlorhexidine solution used in GSK’s Corsodyl mouthwash into a gel to prevent umbilical cord infections. This issue is exacerbated in developing countries, where many births take place at home and without proper health care.
Every year millions of people are displaced by disasters and emergency situations. These crises can devastate families, leaving them without access to adequate food, shelter or healthcare. GSK works with partners and humanitarian organisations to prepare for and respond to emergency situations. In some instances, we fast-track the development of life-saving vaccines, and in others, we contribute by donating cash, products and our employees’ time. We also invest in long-term rebuilding and reconstruction in the aftermath of a disaster.
In 2015 we donated £1.1million to support efforts to address the global refugee crisis.
We donated medicines valued at £136.9 million. This support includes our Patient Assistance Programmes, over 900 million albendazole tablets to fight lymphatic filariasis and soil-transmitted helminths and product donations to support humanitarian aid, distributed through our partners AmeriCares, Direct Relief, IMA World Health, MAP International and Project HOPE.
Rewarding innovation in healthcare
In February 2016, we announced the winners of the third annual $1 million Healthcare Innovation Award, set up by GSK and Save the Children to reward sustainable and scalable healthcare innovations that have resulted in tangible improvements to under-five child survival rates. The 2016 winners include innovations in strengthening health systems, community programmes and treatment strategies from Africa, Asia and South America. The overall winner was a digital immunisation system developed by PATH in South Vietnam.